MENS (Jyong Biotech) Tariff Resilience Score: 0/10 (As of Jul. 05, 2026)


MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.22
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech Tariff Resilience Score?

Jyong Biotech has the Tariff Resilience Score of 0, which implies that the company might have .

Jyong Biotech has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Jyong Biotech might have .

Jyong Biotech  (NAS:MENS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Jyong Biotech Tariff Resilience Score Related Terms

MENS
10GF Score
Jyong Biotech Ltd MENS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price